Pasar al contenido principal

LA INHIBICION DEL RECEPTOR SIGMA-1: UNA NUEVA ESTRATEGIA PARA EL TRATAMIENTO DEL DOLOR POSTOPERATORIO

PID2019-108691RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The sigma-1 receptor curtails endogenous opioid analgesia during sensitization of TRPV1 nociceptors

  • Ruiz-Cantero, M. Carmen
  • Cortés-Montero, Elsa
  • Jain, A.
  • Montilla-García, Ángeles
  • Bravo-Caparros, I.
  • Shim, J.
  • Sánchez-Blázquez, Pilar
  • Woolf, CJ.
  • Baeyens, José M.
  • Cobos, Enrique J.
Background and PurposePeripheral sensitization contributes to pathological pain. While prostaglandin E2 (PGE2) and nerve growth factor (NGF) sensitize peptidergic C-nociceptors (TRPV1+), glial cell line-derived neurotrophic factor (GDNF) sensitizes non-peptidergic C-neurons (IB4+). The sigma-1 receptor (sigma-1R) is a Ca2+-sensing chaperone known to modulate opoid analgesia. This receptor binds both to TRPV1 and the mu opioid receptor, although the functional repercussions of these physical interactions in peripheral sensitization are unknown.Experimental ApproachWe tested the effects of sigma-1 antagonism on PGE2-, NGF-, and GDNF-induced mechanical and heat hyperalgesia in mice. We used immunohistochemistry to determine the presence of endomorphin-2, an endogenous mu receptor agonist, on dorsal root ganglion (DRG) neurons. Recombinant proteins were used to study the interactions between sigma-1R, mu- receptor, and TRPV1. We used calcium imaging to study the effects of sigma-1 antagonism on PGE2-induced sensitization of TRPV1+ nociceptors.Key ResultsSigma1 antagonists reversed PGE2- and NGF-induced hyperalgesia but not GDNF-induced hyperalgesia. Endomorphin-2 was detected on TRPV1+ but not on IB4+ neurons. Peripheral opioid receptor antagonism by naloxone methiodide or administration of an anti-endomorphin-2 antibody to a sensitized paw reversed the antihyperalgesia induced by sigma-1 antagonists. Sigma-1 antagonism transfers sigma-1R from TRPV1 to mu receptors, suggesting that sigma-1R participate in TRPV1-mu receptor crosstalk. Moreover, sigma-1 antagonism reversed, in a naloxone-sensitive manner, PGE2-induced sensitization of DRG neurons to the calcium flux elicited by capsaicin, the prototypic TRPV1 agonist.Conclusion and ImplicationsSigma-1 antagonism harnesses endogenous opioids produced by TRPV1+ neurons to reduce hyperalgesia by increasing mu receptor activity., Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía, Grant/Award Number: CTS109; European Regional Development Fund; Secretaría de Estado de Investigación, Desarrollo e Innovación, Grant/Award Numbers: FPU 15/02356 (E Cortés-Montero), FPU16/03213 (MC Ruiz-Cantero), PID2019-108691RB-I00, SAF2016-80540-R; Universidad de Granada, Grant/Award Number: PPJIB2019.11; Universidad de Granada / CBUA; Harvard Medical School - Blavatnik Sensory Disorders Research Award, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The proof of concept of 2-{3-[N-(1-benzylpiperidin-4-yl)propyl]amino}-6-[N-methyl-N-(prop-2-yn-1-yl)amino]-4-phenylpyridine-3,5-dicarbonitrile for the therapy of neuropathic pain

  • Entrena, J. M.
  • Artacho-Cordón, A.
  • Ravez, S.
  • Liberelle, M.
  • Melnyk, P.
  • Toledano-Pinedo, M.
  • Almendros, Pedro
  • Cobos, E. J.
  • Marco-Contelles, José
In the search for new small molecules for the therapy of neuropathic pain, we found that 2-{3-[N-(1-benzylpiperidin-4-yl)propyl]amino}-6-[N-methyl-N-(prop-2-yn-1-yl)amino]-4-phenylpyridine-3,5-dicarbonitrile (12) induced a robust antiallodynic effect in capsaicin-induced mechanical allodynia, a behavioural model of central sensitization, through σR antagonism. Furthermore, administration of compound 12 to neuropathic animals, fully reversed mechanical allodynia, increasing its mechanical threshold to levels that were not significantly different from those found in paclitaxel-vehicle treated mice or from basal levels before neuropathy was induced. Ligand 12 is thus a promising hit-compound for the therapy of neuropathic pain., This study was partially supported by the Spanish Research Agency (https://doi.org/10.13039/501100011033) under the auspices of MINECO (grant number PID2019-108691RB-I00) and the Andalusian Regional Government (grant CTS109)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M. Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., this work was funded by the spanish Ministerio de ciencia, innovación y universidades, Miciu/aei/10.13039/501100011033: Grants PiD2020-118127RB-i00 and PiD2023-147004OB-i00 (to s.V.), PiD2019-108691RB-i00 (to e.J.c.),PDc2021-121096 (to M.P. and c.s.), PiD2021-127693OB-i00 (to c.G.), PiD2022-141676NB-i00 (to F.F.);PiD2021-129034NB-i00 and PDc2022-133950-i00 (to s.O.); the Generalitat de catalunya (2021 sGR 00357 and 2021sGR 00487); the european Research council (eRc-2015-stG-679001-NetMoDezyme and eRc-2022-coG-101088032 tos.O.); the Xunta de Galicia (eD431c 2022/20); and the european Regional Development Fund (eRDF); Ministry ofscience and innovation, spain, with funds from the european union NextGenerationeu (PRtRc17.i1) and theautonomous community of Galicia within the framework of the 2023 Biotechnology Plan applied to health (to M.i.l.and J.B.). Partial support was provided by Nih-Niehs River award R35 es030443 and, Nih-Niehs superfund ProgramP42 es004699 to B.D.h. the content is solely the responsibility of the authors and does not necessarily represent theofficial views of the National institutes of health. M.R.c. was granted access to i24 beamline by the Diamond lightsource for (proposal number: MX32787). s.c. and a.l.t. received PhD fellowships from the universitat de Barcelona(aPiF grant) and the spanish Ministerio de educación, cultura y Deporte (FPu15/00889 grant), respectively. a.B.-M.,c.e., and M.s.-c. were supported by the Research Personnel training Program (FPi grants PRe2019-087468,PRe2022-104952, and PRe2020-096203, respectively) of the spanish Ministerio de ciencia, innovación y universidades(Miciu) and agencia estatal de investigación (aei). Q.Q. is funded by the King’s-china scholarship council PhDscholarship programme. F.F. received spanish MiciNN for a Ramón y cajal fellowship (RYc2020-029552-i). c.c.-t.received science Postdoctoral Fellowship from a schmidt Futures program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain [Dataset]

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033: Grants PID2020-118127RB-I00 and PID2023-147004OB-I00 (to S.V.), PID2019-108691RB-I00 (to E.J.C.), PDC2021-121096 (to M.P. and C.S.), PID2021-127693OB-I00 (to C.G.), PID2022-141676NB-I00 (to F.F.); PID2021-129034NB-I00 and PDC2022-133950-I00 (to S.O.); the Generalitat de Catalunya (2021 SGR 00357 and 2021 SGR 00487); the European Research Council (ERC-2015-StG-679001-NetMoDEzyme and ERC-2022-CoG-101088032 to S.O.); the Xunta de Galicia (ED431C 2022/20); and the European Regional Development Fund (ERDF); Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health (to M.I.L. and J.B.). Partial support was provided by NIH-NIEHS River Award R35 ES030443 and, NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.R.C. was granted access to I24 beamline by the Diamond Light Source for (proposal number: MX32787). S.C. and A.L.T. received PhD fellowships from the Universitat de Barcelona (APIF grant) and the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/00889 grant), respectively. A.B.-M., C.E., and M.S.-C. were supported by the Research Personnel Training Program (FPI grants PRE2019-087468, PRE2022-104952, and PRE2020-096203, respectively) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI). Q.Q. is funded by the King’s-China Scholarship Council PhD Scholarship programme. F.F. received Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). C.C.-T. received Science Postdoctoral Fellowship from a Schmidt Futures program., Peer reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

2-{N-[ω-(1-Benzylpiperidin-4-yl)alkyl]amino}-6-[(prop-2-yn-1-yl)amino]pyridine-3,5-dicarbonitriles Showing High Affinity forσ1/2 Receptors

  • Deuther Conrad, Winnie
  • Schepmann, Dirk
  • Iriepa Canalda, Isabel|||0000-0003-3475-9624
  • López Muñoz, Francisco
  • Chioua, Mourad
  • Wünsch, Bernhard
  • Samadi, Abdelouahid
  • Marco Contelles, José Luis
Sigma receptors (sigma Rs) represent very attractive biological targets for the development of potential agents for the treatment of several neurological disorders. In the search for new small molecule drugs against neuropathic pain, we identified 2-{[2-(1-benzylpiperidin-4-yl)ethyl]amino}-6-[methyl(prop-2-yn-1-yl)amino]pyridine-3,5-dicarbonitrile (5) as a polyfunctionalized small pyridine with potent dual-target activities against acetylcholinesterase (AChE) (IC50 = 13 nM) and butyrylcholinesterase (BuChE) (IC50 = 3.1 mu M), exhibiting high sigma 1R affinity (Ki(h sigma 1R) = 1.45 nM) and 290-fold selectivity over the sigma 2R subtype. These results are in good agreement with those found in the molecular modeling of compound 5. This is possibly due to the preferred combination in this molecule of a linker n = 2 connecting the N-Bn-piperidine motif to the C2 pyridine, without a phenyl group at C4, and a N-Me-substituted propargyl amine in the chain located at C6., Ministerio de Ciencia, Innovación y Universidades